Allogene Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Allogene Therapeutics, Inc. carries a market capitalization of 511.00M, placing it among publicly traded companies globally. Its enterprise value stands at 359.19M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 511.00M |
| Enterprise Value | 359.19M |
Share Statistics
Allogene Therapeutics, Inc. currently has 244.82M shares outstanding.
| Shares Outstanding | 244.82M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.27 |
| P/TBV Ratio | 1.98 |
| P/FCF Ratio | -5.08 |
| P/OCF Ratio | -5.07 |
Financial Position
Allogene Therapeutics, Inc. maintains a current ratio of 9.65, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.05, indicating elevated leverage, while an interest coverage ratio of -143.43 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.65 |
| Quick Ratio | 9.42 |
| Debt / Equity | 26.05 |
| Debt / EBITDA | -0.41 |
| Interest Coverage | -143.43 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -38.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Allogene Therapeutics, Inc.'s stock has gained approximately 80.63793% over the past 52 weeks. The 50-day moving average sits at 2.10, while the 200-day moving average is 1.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | 80.63793% |
| 50-Day Moving Average | 2.10 |
| 200-Day Moving Average | 1.80 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -175.70M, while operating income came in at -187.83M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -187.83M |
| Pretax Income | -173.76M |
| Net Income | -173.76M |
| EBITDA | -175.70M |
| EBIT | -187.83M |
| Earnings Per Share (EPS) | -0.77 |
Balance Sheet
Allogene Therapeutics, Inc. holds 266.89M in cash and equivalents against 72.63M in total debt, resulting in a net debt position of -30.31M. Total book value stands at -2.05B, with working capital of 244.96M providing operational flexibility.
| Cash & Cash Equivalents | 266.89M |
| Total Debt | 72.63M |
| Net Debt | -30.31M |
| Equity (Book Value) | -2.05B |
| Book Value Per Share | -9.05 |
| Working Capital | 244.96M |
Cash Flow
Allogene Therapeutics, Inc. produced -109.23M in operating cash flow over the past twelve months. After subtracting -296,000.00 in capital expenditures, free cash flow totaled -109.53M - equivalent to -0.48 per share.
| Operating Cash Flow | -109.23M |
| Capital Expenditures | -296,000.00 |
| Free Cash Flow | -109.53M |
| FCF Per Share | -0.48 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -6.74 |
| FCF Yield | -19.68 |
Scores
Allogene Therapeutics, Inc. posts an Altman Z-Score of -5.25, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.25 |